Chen, Kuan-HsuanKuan-HsuanChenHsu, Chuan-ChihChuan-ChihHsuSong, Wen-ShinWen-ShinSongHuang, Chi-ShuanChi-ShuanHuangTsai, Chia-ChenChia-ChenTsaiKuo, Cheng-DengCheng-DengKuoHsu, Han-ShuiHan-ShuiHsuTsai, Tung-HuTung-HuTsaiTsai, Ching-YaoChing-YaoTsaiLIN-CHUNG WOUNGChiou, Shih-HwaShih-HwaChiouLu, Kai-HsiKai-HsiLuChen, Yi-WeiYi-WeiChen2024-01-292024-01-292010-1102567040https://scholars.lib.ntu.edu.tw/handle/123456789/639032Cyclooxygenase-2 (COX-2), the enzyme that converts arachidonic acid to prostaglandins, is overexpressed in a variety of tumors, including medulloblastoma (MB). CD133, a transmembrane glycoprotein, has been suggested as a marker for cancer stem cells in brain tumors. The aim of the present study was to investigate the role of celecoxib, a selective COX-2 inhibitor, in enhancing the effects of ionizing radiotherapy (IR) on medulloblastoma-derived CD133-positive cells (MB-CD133(+)).enCD133 | Celecoxib | Daoy | Medulloblastoma | Radiosensitivityjournal article10.1007/s00381-010-1190-2205267172-s2.0-78649326726https://api.elsevier.com/content/abstract/scopus_id/78649326726